Primrose Bio Earns $2M NIH Award for RNA Therapeutics
SAN DIEGO, Calif., July 15, 2026 Primrose Bio, Inc. has secured a $2 million Direct-to-Phase II Small Business Innovation...
RNA therapeutics
Advertisement
Atrium Therapeutics Launches Phase 1/2 Trial for ATR 1072
SAN DIEGO, Calif., July 14, 2026 Atrium Therapeutics has achieved an important regulatory milestone after the U.S. Food and...
AstraZeneca Reports Wainua Phase III ATTR-CM Trial Results
CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...
Immunomic Therapeutics Doses First Patient in ITI-9001 Trial
ROCKVILLE, Maryland, July 4, 2026 Immunomic Therapeutics Inc. (ITI), a clinical-stage biotechnology company and subsidiary of HLB, has announced...
CSPC Pharma Secures Up to $1.77B AstraZeneca siRNA Deal
HONG KONG, July 2, 2026 CSPC Pharmaceutical Group Limited has announced a strategic collaboration, option and license agreement with...
Advertisements
Arcturus Therapeutics Partners With Thermo Fisher for ARCT-032
SAN DIEGO, Calif., July 2, 2026 Arcturus Therapeutics Holdings Inc. announced a strategic collaboration with Thermo Fisher Scientific to...
ARTAN Bio Secures $1M Seed Round for tRNA Platform
ST. PETERSBURG, Fla., July 1, 2026 ARTAN Bio has announced the successful completion of a $1 million seed financing...
PleoPharma Launches Phase 3 Trial for Cannabis Withdrawal
PHOENIXVILLE, Pa., June 20, 2026 PleoPharma, Inc. has announced the dosing of the first patient in CAN-004, its pivotal...
New Gates Foundation Grant Fuels Replicate’s Fight Against Tuberculosis
SAN DIEGO, Calif., June 20, 2026 Replicate Bioscience has secured a $3 million research grant from the Gates Foundation...
Novartis Del-Brax Shows Breakthrough Potential in FSHD
BASEL, Switzerland, June 11, 2026 Novartis has announced positive results from the FORTITUDE Phase I/II clinical study evaluating delpacibart...
Advertisement
